Literature DB >> 28389709

[Familial chilblain lupus : Type 1 interferonopathy with model character].

C Fiehn1.   

Abstract

Familial chilblain lupus belongs to the group of type 1 interferonopathies and is particularly characterized by typical skin manifestations and ischemia of the acra. There are various mutations that can lead to this autosomal dominant disease. A mutation in the TREX-1 gene has been most frequently found; however, families with mutations in the SAMHD1 gene and recently in the gene which codes for the stimulator of interferon genes (STING) protein were also described. A common feature of these genetic defects is that they are all involved in the process of detection of intracellular free DNA, which as a result leads to increased production of type 1 interferons and the induced gene products. This then leads to autoinflammation and autoimmunity, which is characteristic for the disease. The activation of interferon-induced genes is controlled by the JAK-STAT system; therefore, JAK inhibitors were successfully used in several cases to treat type 1 interferonopathies. Experience with this treatment modality is continuously growing.

Entities:  

Keywords:  Autoimmunity; Autoinflammation; Autosomal dominant; JAK inhibitors; Mutation

Mesh:

Substances:

Year:  2017        PMID: 28389709     DOI: 10.1007/s00393-017-0285-5

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.372


  34 in total

Review 1.  [Type I interferonopathies. Systemic inflammatory diseases triggered by type I interferons].

Authors:  C Günther; F Schmidt; N König; M A Lee-Kirsch
Journal:  Z Rheumatol       Date:  2016-03       Impact factor: 1.372

2.  Exonuclease TREX1 degrades double-stranded DNA to prevent spontaneous lupus-like inflammatory disease.

Authors:  Jessica L Grieves; Jason M Fye; Scott Harvey; Jason M Grayson; Thomas Hollis; Fred W Perrino
Journal:  Proc Natl Acad Sci U S A       Date:  2015-04-06       Impact factor: 11.205

3.  JAK inhibition in STING-associated interferonopathy.

Authors:  Mathieu P Rodero; Marie-Louise Frémond; Gillian I Rice; Bénédicte Neven; Yanick J Crow
Journal:  Ann Rheum Dis       Date:  2016-10-12       Impact factor: 19.103

4.  Response to: 'JAK inhibition in STING-associated interferonopathy' by Crow et al.

Authors:  Victoria Tüngler; Nadja König; Claudia Günther; Kerstin Engel; Christoph Fiehn; Martin Smitka; Maja von der Hagen; Reinhard Berner; Min Ae Lee-Kirsch
Journal:  Ann Rheum Dis       Date:  2016-11-03       Impact factor: 19.103

5.  Stimulator of Interferon Genes-Associated Vasculopathy With Onset in Infancy: A Mimic of Childhood Granulomatosis With Polyangiitis.

Authors:  Justine Munoz; Michel Rodière; Nadia Jeremiah; Frédéric Rieux-Laucat; Anthony Oojageer; Gillian I Rice; Flore Rozenberg; Yanick J Crow; Didier Bessis
Journal:  JAMA Dermatol       Date:  2015-08       Impact factor: 10.282

6.  Efficacy of the Janus kinase 1/2 inhibitor ruxolitinib in the treatment of vasculopathy associated with TMEM173-activating mutations in 3 children.

Authors:  Marie-Louise Frémond; Mathieu Paul Rodero; Nadia Jeremiah; Alexandre Belot; Eric Jeziorski; Darragh Duffy; Didier Bessis; Guilhem Cros; Gillian I Rice; Bruno Charbit; Anne Hulin; Nihel Khoudour; Consuelo Modesto Caballero; Christine Bodemer; Monique Fabre; Laureline Berteloot; Muriel Le Bourgeois; Philippe Reix; Thierry Walzer; Despina Moshous; Stéphane Blanche; Alain Fischer; Brigitte Bader-Meunier; Fréderic Rieux-Laucat; Yanick Joseph Crow; Bénédicte Neven
Journal:  J Allergy Clin Immunol       Date:  2016-08-20       Impact factor: 10.793

7.  Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus.

Authors:  Emily C Baechler; Franak M Batliwalla; George Karypis; Patrick M Gaffney; Ward A Ortmann; Karl J Espe; Katherine B Shark; William J Grande; Karis M Hughes; Vivek Kapur; Peter K Gregersen; Timothy W Behrens
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-25       Impact factor: 11.205

8.  Familial chilblain lupus due to a gain-of-function mutation in STING.

Authors:  Nadja König; Christoph Fiehn; Christine Wolf; Max Schuster; Emanuel Cura Costa; Victoria Tüngler; Hugo Ariel Alvarez; Osvaldo Chara; Kerstin Engel; Raphaela Goldbach-Mansky; Claudia Günther; Min Ae Lee-Kirsch
Journal:  Ann Rheum Dis       Date:  2016-08-26       Impact factor: 19.103

9.  A progressive familial encephalopathy in infancy with calcifications of the basal ganglia and chronic cerebrospinal fluid lymphocytosis.

Authors:  J Aicardi; F Goutières
Journal:  Ann Neurol       Date:  1984-01       Impact factor: 10.422

10.  Trex1 prevents cell-intrinsic initiation of autoimmunity.

Authors:  Daniel B Stetson; Joan S Ko; Thierry Heidmann; Ruslan Medzhitov
Journal:  Cell       Date:  2008-08-22       Impact factor: 41.582

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.